ProPhase Labs, Inc. Gain (Loss) on Investments
ProPhase Labs, Inc. (PRPH) reported Gain (Loss) on Investments of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnInvestments · last filed 2024-03-29
- ProPhase Labs, Inc. gain (loss) on investments for the quarter ending 2023-12-31 was $0.00.
- ProPhase Labs, Inc. gain (loss) on investments for the quarter ending 2023-09-30 was $0.00.
- ProPhase Labs, Inc. gain (loss) on investments for the quarter ending 2023-06-30 was $0.00.
- ProPhase Labs, Inc. gain (loss) on investments for the quarter ending 2023-03-31 was $0.00.
- ProPhase Labs, Inc. gain (loss) on investments for fiscal 2023 was $0.00.
- ProPhase Labs, Inc. gain (loss) on investments for fiscal 2022 was -$76.00K.
- ProPhase Labs, Inc. gain (loss) on investments for fiscal 2021 was -$240.00K.
| Period end | Gain (Loss) on Investments 3 month | Gain (Loss) on Investments 6 month | Gain (Loss) on Investments 9 month | Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 10-K · filed 2024-03-29 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 derived: sum of 4 quarters · filed 2024-03-29 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | -$76.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | -$76.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-11 | -$76.00K 10-Q · filed 2023-08-11 | ||
| 2021-12-31 | -$240.00K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |